Aerska emerges from stealth to combat brain diseases with RNAi

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Startup’s ‘brain shuttle’ tech is designed to efficient, repeatable delivery of genetic medicines across the blood–brain barrier.

Irish biotech Aerska has emerged from stealth with $21 million in seed financing as it seeks to advance new RNA interference medicines specifically designed to reach the brain. Based in Dublin with research operations in London, the company is focused on tackling one of the most intractable problems in medicine: delivering genetic therapies across the blood-brain barrier to treat neurodegenerative diseases.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3508

Aerska

Longevity level(s):

  • Level 5: Aging disease management
    Therapeutic interventions that manage the symptoms of diagnosed aging diseases (i.e. current mainstream healthcare) and biotechnology companies focused on developing drugs to treat age-related diseases.
  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.

Overview

Aerska is a biotechnology company developing RNA interference (RNAi) therapeutics designed to treat neurological diseases by silencing disease-causing genes. The company employs a proprietary antibody-oligo conjugate (AOC) platform with brain shuttle mechanisms to overcome the blood-brain barrier and enable systemic delivery of RNA medicines to the central nervous system. Aerska focuses on precision medicine approaches targeting genetic forms of Alzheimer's disease and Parkinson's disease, with the broader mission of preserving cognitive function and extending healthspan in patients with neurodegenerative conditions.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE